Neurology News

Among participants in a decades-long prospective cohort study, risk for dementia significantly increased after ischemic stroke, according to results published in JAMA Neurology.

The long-term use of IV edaravone in patients with ALS, although tolerated, did not produce significant improvement compared with standard therapies alone, according to a study published in JAMA Neurology.

Disease-modifying antirheumatic drugs did not appear to be linked to a lower risk for Parkinson’s disease among individuals with rheumatoid arthritis, according to results of a nested case-control study published in Neurology.

The FDA has granted priority review to PTC Therapeutics Inc. for a supplemental new drug application regarding Evrysdi, according to a company release.

Heart disease continues to stand as the leading global cause of death, but there has been a rapid rise in brain disease-related deaths, and risk factors for both are similar, according to an American Heart Association report.

Pose estimation may be a quick, accurate alternative for measuring full-body movements during neurological examinations, according to a pilot study published in PLOS One.

Healio announced the first year’s honorees of its new recognition program, Healio Honors, according to a press release.

The FDA granted breakthrough device designation to Amprion for its SYNTap Test, which detects a distinct protein as an indicator of Alzheimer’s disease with Lewy bodies, according to a news release.

The Medicare Payment Advisory Commission, or MedPAC, recommended no change to the physician fee schedule for 2023, a decision that the ACP and AMA described as a freezing of physician payments.

Clinical trial sponsors said they have adopted new methods and decentralized procedures that may increase diversity and inclusion in future trials.